# SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

> **NCT03614949** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 21 (actual)

## Conditions studied

- Cervical Cancer
- Cervical Cancer Recurrent
- Cervical Cancer Metastatic

## Interventions

- **RADIATION:** Stereotactic body radiation therapy (SBRT)
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03614949
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-29
- **Primary completion:** 2028-10
- **Final completion:** 2028-10
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03614949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03614949, "SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03614949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*